CN113507961A - FAPα特异性的双环肽配体 - Google Patents

FAPα特异性的双环肽配体 Download PDF

Info

Publication number
CN113507961A
CN113507961A CN201980089032.4A CN201980089032A CN113507961A CN 113507961 A CN113507961 A CN 113507961A CN 201980089032 A CN201980089032 A CN 201980089032A CN 113507961 A CN113507961 A CN 113507961A
Authority
CN
China
Prior art keywords
peptide ligand
peptide
acid
seq
fap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089032.4A
Other languages
English (en)
Chinese (zh)
Inventor
L·陈
C·斯泰斯
E·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bicycle Therapeutics PLC
Original Assignee
Bicycle Therapeutics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycle Therapeutics PLC filed Critical Bicycle Therapeutics PLC
Publication of CN113507961A publication Critical patent/CN113507961A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980089032.4A 2018-12-13 2019-12-13 FAPα特异性的双环肽配体 Pending CN113507961A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1820320.8A GB201820320D0 (en) 2018-12-13 2018-12-13 Bicyclic peptide ligands specific for FAPalpha
GB1820320.8 2018-12-13
PCT/GB2019/053535 WO2020120979A1 (en) 2018-12-13 2019-12-13 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPα

Publications (1)

Publication Number Publication Date
CN113507961A true CN113507961A (zh) 2021-10-15

Family

ID=65147028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980089032.4A Pending CN113507961A (zh) 2018-12-13 2019-12-13 FAPα特异性的双环肽配体

Country Status (6)

Country Link
US (1) US20220008545A1 (https=)
EP (1) EP3894005A1 (https=)
JP (1) JP2022515721A (https=)
CN (1) CN113507961A (https=)
GB (1) GB201820320D0 (https=)
WO (1) WO2020120979A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
CN111118063B (zh) * 2019-12-05 2023-04-18 吉林大学 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176622A1 (en) * 2002-09-18 2005-08-11 Kerstin Kuhn-Wache Secondary binding site of dipeptidyl peptidase IV (DPIV)
US20060172938A1 (en) * 2004-10-12 2006-08-03 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
CN103945856A (zh) * 2011-08-30 2014-07-23 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂
CN107531776A (zh) * 2015-03-17 2018-01-02 生物技术公司 用于诊断和治疗癌症的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
DK1844337T3 (da) 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
AU2009211253B2 (en) 2008-02-05 2014-11-06 Bicyclerd Limited Methods and compositions
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
WO2018197893A1 (en) * 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176622A1 (en) * 2002-09-18 2005-08-11 Kerstin Kuhn-Wache Secondary binding site of dipeptidyl peptidase IV (DPIV)
US20060172938A1 (en) * 2004-10-12 2006-08-03 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
CN103945856A (zh) * 2011-08-30 2014-07-23 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂
CN107531776A (zh) * 2015-03-17 2018-01-02 生物技术公司 用于诊断和治疗癌症的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN HEINIS 等: "Phage-encoded combinatorial chemical libraries based on bicyclic peptides", NATURE CHEMICAL BIOLOGY, vol. 5, no. 7, pages 503 *

Also Published As

Publication number Publication date
US20220008545A1 (en) 2022-01-13
JP2022515721A (ja) 2022-02-22
WO2020120979A1 (en) 2020-06-18
EP3894005A1 (en) 2021-10-20
GB201820320D0 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
CN113507960A (zh) Psma特异性的双环肽配体
CN113383007A (zh) Caix特异性的双环肽配体
US11623012B2 (en) Bicyclic peptide ligands specific for EphA2
CN113383074A (zh) Caix特异性的双环肽配体
JP2025020121A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
CN113543813B (zh) Cd38特异性的双环肽配体
KR102754019B1 (ko) Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
CN114555626A (zh) 异串联双环肽复合物
CN113260420A (zh) Pd-l1特异性的双环肽配体
CN113613728A (zh) 整联蛋白αvβ3特异性的双环肽配体
CN113439088A (zh) 整联蛋白αvβ3特异性的双环肽配体
WO2019025811A1 (en) SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
EP3452096A1 (en) Bicyclic peptide-toxin conjugates specific for mt1-mmp
CN113474047A (zh) Mt1-mmp特异性的双环肽配体
CN113518648A (zh) Mt1-mmp特异性的双环肽配体
CN113474046A (zh) Il-17特异性的双环肽配体
CN113507961A (zh) FAPα特异性的双环肽配体
CN114787177A (zh) Il-17特异性的双环肽配体
CN114867736A (zh) Il-17特异性的双环肽配体
CN114829376A (zh) Il-17特异性的双环肽配体
CN114787176A (zh) Il-17特异性的双环肽配体
HK40080423A (en) Bicyclic peptide ligands specific for epha2
HK40058108A (en) Bicyclic peptide ligands specific for mt1-mmp

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211015